Silence Therapeutics PLC · NASDAQ:SLN
Silence Therapeutics — 39th Annual Cowen Health Care Conference 2019
27 slides from Silence Therapeutics's conference presentation, Mar 11, 2019
Slide 1: 39th Annual Cowen Health Care Conference
39th Annual Cowen Health Care Conference 11 March 2019
Slide 2: Disclaimer (US)
Disclaimer (US) The information contained in this presentation is being supplied and communicated Safe Harbour statement: this presentation may contain forward-looking statements to you on a confidential basis solely for your information and may not be reproduced, that reflect the Company’s current
Slide 3: Silence Therapeutics' Summary
Silence Therapeutics’ Summary • Reproducible, proprietary gene silencing (RNAi) therapeutics platform, HQ in London Valuable Platform rapidly generating internal pipeline and diversifying out-licensing options • SLN124 (beta-thalassemia & MDS1) to enter the clinic in 2019, with Haematology first pat
Slide 4: Full Year Results – Highlights
Full Year Results – Highlights Operational Highlights • Lead candidate SLN124 granted Orphan Drug Designation by the European Medicines Agency for the treatment of β-Thalassemia • CTA filing expected shortly • First patients expected to enter a Phase Ib study in H2 2019 • SLN360, an Lp(a) targeting
Slide 5: Experienced Leadership Team
Experienced Leadership Team Deep Background in Discovery & Development of RNA Therapies With Strong Biopharma Experience David Horn Solomon Marie Wikstrom Lindholm Rob Quinn, Richard Jenkins CEO & President CEO VP Technology Innovation Interim CFO VP Clinical Development Since 2018 Since 2018 Since
Slide 6: Reproducibly silencing disease-associated genes using our proprietary platform technology
Reproducibly silencing disease-associated genes using our proprietary platform technology Platform technology with freedom Target 1 Target 2 to operate: GalNAc-siRNA, able to mediate highly specific gene silencing N o r m a lis e d ta r g e t m R N A N o r m a lis e d ta r g e t m R N A in hepatocyt
Slide 7: Our Pipeline
Our Pipeline Out-Licensed Technology to Quark Pharmaceuticals © Silence Therapeutics 2018 © Silence Therapeutics 2019 7
Slide 8: SLN124 for the treatment of Iron Overload Disorders
SLN124 for the treatment of Iron Overload Disorders © Silence Therapeutics 2019 8
Slide 9: Market Opportunity of SLN124
Market Opportunity of SLN124 US and EU patients Standard of Care β-Thalassemia ~40,000 TDT1 ~20,000 NTDT2 MDS3 >100,000 Benefits of SLN124 Advantages Competition SoC: Quality of Life Transfusions + Chelators SLN124 aims to: 1. Reduce organ iron levels & Safety Antisense RNA 2. Enhance erythropoiesis
Slide 10: SLN124 Mechanism of Action: Increasing Hepcidin by Silencing its Repressor TMPRSS6
SLN124 Mechanism of Action: Increasing Hepcidin by Silencing its Repressor TMPRSS6 HJV BMPR Macrophages • TMPRSS6 (Transmembrane BMP Protease, Serine 6) is a negative regulator of the Ferroportin BMP/SMAD signaling TMPRSS6 P Fe pathway Iron recycling • Inhibition of TMPRSS6 in P SMAD hepatocytes ind
Slide 11: SLN124 Lowers Iron Levels for at Least 6 Weeks after Single Administration in Mice
SLN124 Lowers Iron Levels for at Least 6 Weeks after Single Administration in Mice Study design d1 wk 1 wk 3 wk 6 SC, n=4 mice, 3 mg/kg TMPRSS6 mRNA (liver) Iron (serum) 40 1 .0 N o r m a lis e d T M P R S S 6 m R N A S e ru m iro n [µ m o l/L ] 30 20 0 .5 10 0 .0 0 1 1 3 6 w eeks 1 1 3 6 weeks PBS
Slide 12: Therapeutic Activity of SLN124 in a Disease Model of Hereditary Haemochromatosis
Therapeutic Activity of SLN124 in a Disease Model of Hereditary Haemochromatosis (HFE-/- mice) Collaboration with Study design d1 wk 3 Prof. Dr. Martina Muckenthaler Heidelberg University, Germany SC, n=6-7 HFE-/- mice TMPRSS6 mRNA (liver) Hepcidin (serum) Iron (serum) 2 .0 800 p<0.0001 N o r m a li
Slide 13: SLN124 Reduces ROS and Improves RBC Parameters in a β-Thalassemia Disease Model
SLN124 Reduces ROS and Improves RBC Parameters in a β-Thalassemia Disease Model Collaboration with Study design d1 wk 2 wk 5 Prof. J. Vadolas & Dr. Grigoriadis Monash Medical Centre/Melbourne, Australia SC, n=6-8 Hbbth3/+ mice Reactive oxygen species (ROS) Reticulocyte proportion Haematocrit p = 0 .
Slide 14: Planning a Multicentre, Randomised, Placebo Controlled Phase 1b in 2019
We are Planning to Initiate a Multicentre, Randomised, Placebo Controlled Phase 1b in 2019 This is a two part first-in-human, multicenter, randomized placebo controlled single ascending and multiple dose study to assess the preliminary safety, tolerability, PK and efficacy of SLN124 administered sub
Slide 15: SLN124 Summary
SLN124 Summary • Preclinical package: Robust data generated in several disease models. • Status: Non-clinical development work ongoing, with CTA filing expected in Q2 2019. Orphan Designation granted for β−Thalassaemia and application planned for MDS. • Clinical plans: Phase 1b planned in patients (
Slide 16: SLN360 for the treatment of Cardiovascular disease with high Lp(a)
SLN360 for the treatment of Cardiovascular disease with high Lp(a) © Silence Therapeutics 2019 16
Slide 17: SLN360 targets Lp(a) - an Independent Risk Factor for CVD
SLN360 targets Lp(a) - an Independent Risk Factor for CVD > Lp(a) is a lipoprotein involved in the transportation of lipids. > Lp(a) is a validated target in humans. Lp(a) excess is detected in patients with premature CVD: • High Lp(a) is associated with CHD, unstable angina, myocardial infarction (
Slide 18: Lp(a) has Prothrombotic, Proinflammatory and Proatherogenic Properties
Lp(a) has Prothrombotic, Proinflammatory and Proatherogenic Properties Proinflammatory Macrophage IL-8 expression Monocyte chemotaxis/transmigration Monocyte cytokine release Monocyte cytokine release Carries MCP-1 Lp(a) activities Proatherogenic Prothrombotic EC binding Plasminogen activation Upreg
Slide 19: Serum Lp(a) reduction: Proof of mechanism achieved
Proof of mechanism achieved Serial serum collection 1 5 0 L p (a ) le v e ls ± S D ) Serum Lp(a) reduction d-15 d0 d7 d14 d63 C o n tro l s e ru m 1 0 0 3 m g /k g Serum baseline 9 m g /k g siRNA sc N o r m a lis e d B L 3 x 3 m g /k g 5 0 Group mg/kg Days (M e a n 1 0 0 9 0 % R e d u c tio n 0 2 3
Slide 20: SLN360 summary
SLN360 summary Rationale > Lp(a) is a low-density lipoprotein produced predominantly by the liver and composed of Apo(a) and Apo B, both hepatocyte expressed genes. > Genetically defined high Lp(a) serum levels are unaffected by diet and exercise and are an independent risk factor for CVD. There is
Slide 21: Complement-Mediated Diseases
Complement- Mediated Diseases © Silence Therapeutics 2019 21
Slide 22: GalNac siRNAs for the treatment of Complement-mediated diseases
GalNac siRNAs for the treatment of Complement- mediated diseases Schematic overview - complement system Targeting the complement system offers a broad indication spectrum (such as Paroxysmal Nocturnal Hemoglobinuria, Myasthenia gravis, C3 Glomerulopathy, atypical Hemolytic Uremic Syndrome or Cold Ag
Slide 23: Complement-mediated diseases: Proof of Mechanism in vivo (mouse)
Complement-mediated diseases Initial results: Proof of Mechanism in vivo (mouse) d-3 d0 d4 d10 d14 > Study design: • n=4 healthy mice per group, serum sampling at day -3, 4, 10 and 14, liver tissue at day 14 Serum siRNA serum serum Tissue collection • siRNAs: non-optimized GalNac conjugated chemistr
Slide 24: Summary & Outlook
Summary & Outlook © Silence Therapeutics 2019 24
Slide 25: Expected Newsflow & Company Milestones
Expected Newsflow & Company Milestones H1 2019 H2 2019 2020 SLN124 File CTA X First In Human Dosing X First Interim Results X SLN360 Clinical candidate nomination X IND/CTA filing X 2018 New Targets pPOC in mice X Clinical candidate nomination X Platform Strengthening Gen4 toolbox validation and in
Slide 26: Silence Therapeutics' Summary
Silence Therapeutics’ Summary • Reproducible, proprietary gene silencing (RNAi) therapeutics platform, HQ in London Valuable Platform rapidly generating internal pipeline and diversifying out-licensing options • SLN124 (beta-thalassemia & MDS1) planning to enter the clinic in H2 Haematology 2019 aft
Slide 27: < oF CO
< oF CO
Silence Therapeutics — 39th Annual Cowen Health Care Conference 2019 on 6ix